Health Bulletin 27/April/2022

Published On 2022-04-27 11:28 GMT   |   Update On 2022-04-27 11:29 GMT

Here are the top health stories for the day :

NMC denies permission to 3 Medical Colleges, 550 MBBS seats lost

Finding major deficiencies in three major medical institutes in Rajasthan, the National Medical Commission (NMC) has declined its permission for admitting students in the MBBS and PG medical courses offered in those colleges for the academic year 2021-2022.

This has resulted in loss of around 550 MBBS seats as the Apex medical regulator has withdrawn permission for 250 MBBS seats of Geetanjali Medical College and Hospital,150 MBBS seats of Pacific Institute of Medical Sciences, and 150 MBBS seats of American International Institute of Medical Sciences.

For more details, check out the full story on the link below:  

NMC Denies Permission To 3 Medical Colleges, 550 MBBS Seats Lost 


Coronavirus vaccine: DCGI grants emergency use nod to Covaxin, Corbevax, ZycovD for different age group of children

The Drugs Controller General of India (DCGI) on Tuesday approved three Covid vaccines for the restricted emergency use authorisation (EUA) for children of different age groups.

Advertisement

The DCGI gave the restricted emergency use authorisation to Bharat Biotech's Covaxin for children between the age of 6-12 years.

For more details, check out the full story on the link below:

Coronavirus Vaccine: DCGI Grants Emergency Use Nod To Covaxin, Corbevax, ZycovD For Different Age Group Of Children 


NMC warns against circulation of fake allotment letters for MBBS admission, files FIR

Taking action against fake allotment letters for MBBS admission, the National Medical Commission (NMC) has filed a First Information Report in the matter.

Apart from filing the FIR, the apex medical regulatory body has further issued a Public Notice in this regard and warned the aspirants that NMC in not involved in offering admissions to medical courses.

For more details, check out the full story on the link below:

NMC Warns Against Circulation Of Fake Allotment Letters For MBBS Admission, Files FIR 


1,204 fresh Covid cases, one more death in Delhi

According to government's health bulletin, Delhi has reported 1,204 new Covid-19 cases in the last 24 hours. Now, the city's total active cases are 4,508. It is for the fifth continuous day that the national capital has reported over 1,000 cases.

The national capital has witnessed a dip in the Covid positivity rate- 4.64%, as per the Delhi health bulletin.

In the last 24 hours, one Covid death was also reported in Delhi. With a fatality rate of 1.39%, the total tally of deaths caused in the national capital due to the virus now stands at 26,169.

For more news, check out the medical dialogues site:

https://medicaldialogues.in/ 


GSK launches once daily, single inhaler-triple therapy for COPD patients

GlaxoSmithKline Pharmaceuticals Limited has recently launched Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), the first single-inhaler triple therapy (SITT) in India for Chronic Obstructive Pulmonary Disease (COPD) patients in a once-daily regime.

The launch follows the product's approval by the Drugs Controller General of India (DCGI) for use of Trelegy Ellipta as maintenance treatment to prevent and relieve symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) in patients aged 18 and above.

For more details, check out the full story on the link below:   

GSK Launches Single Inhaler-Triple Therapy Trelegy Ellipta To Treat COPD In India 

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News